Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Chenlei Wen
CONTACT
Baiyong Shen
CONTACT
Lead
Ruijin Hospital
With
The study will adopt the standard "3+3" design., with a first-in-human (FIH) dose of 20 μg administered once every four weeks (Q4W). Subsequent dosing frequency will be adjusted based on pharmacodynamics and pharmacokinetics data. The primary objectives of this study are to evaluate the safety and tolerability of ES502 and to determine its maximum tolerated dose (MTD). The secondary objectives are to evaluate its antitumor activity, pharmacokinetics (PK), and pharmacodynamics (PD).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted